Tags

Type your tag names separated by a space and hit enter

Iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer.
Clin Genitourin Cancer. 2013 Sep; 11(3):251-5.CG

Abstract

INTRODUCTION/BACKGROUND

Many localized PCa patients with preexisting LUTS are considered poor candidates for seed implants because of the greater risk of postoperative urinary morbidity. We report our department's experience with performing deferred LTURP 6 months after iodine-125 seed implantation to treat localized PCa patients with LUTS.

PATIENTS AND METHODS

Of 225 men undergoing prostate brachytherapy at our institution between 2005 and 2011, 38 patients were treated with deferred LTURP 6 months after (125)I seed implantation. LTURP was considered after brachytherapy for patients whose International Prostate Symptom Score (IPSS) was greater than 12, or who still need a catheter for an elevated postvoid residual (PVR) (>100 mL) after α-blocker therapy for LUTS for 6 months. IPSS, quality of life (QOL) score, peak flow rate (PFR), and PVR were evaluated before and after LTURP.

RESULTS

All 38 patients in our series underwent LTURP 6 months after prostate brachytherapy for low- or intermediate-risk PCa. Mean IPSS, QOL score, PFR, and PVR were significantly improved after LTURP, and improvement persisted at the latest follow-up. After a mean of 32 months of follow-up, no patient developed retention, urethral necrosis, or urinary incontinence after brachytherapy and LTURP.

CONCLUSION

Iodine-125 seed implantation and deferred LTURP 6 months after brachytherapy is a safe and effective treatment strategy for patients with both LUTS and localized prostate cancer.

Links

Publisher Full Text
Aggregator Full Text
Aggregator Full Text

Authors+Show Affiliations

Liu R
Tianjin Institute of Urology and Department of Urology, Second Hospital, Tianjin Medical University, Tianjin, China.
Luo F
No affiliation info available
Zhang Z
No affiliation info available
Xu Y
No affiliation info available

MeSH

AgedBrachytherapyHumansIodine RadioisotopesMaleProstateProstatic NeoplasmsQuality of LifeSurveys and QuestionnairesTransurethral Resection of ProstateTreatment OutcomeUrinary Tract Infections

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23375828

Citation

Liu, Ranlu, et al. "Iodine-125 Seed Implantation and Deferred Transurethral Resection of the Prostate for Patients With Lower Urinary Tract Symptoms and Localized Prostate Cancer." Clinical Genitourinary Cancer, vol. 11, no. 3, 2013, pp. 251-5.
Liu R, Luo F, Zhang Z, et al. Iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer. Clin Genitourin Cancer. 2013;11(3):251-5.
Liu, R., Luo, F., Zhang, Z., & Xu, Y. (2013). Iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer. Clinical Genitourinary Cancer, 11(3), 251-5. https://doi.org/10.1016/j.clgc.2012.12.010
Liu R, et al. Iodine-125 Seed Implantation and Deferred Transurethral Resection of the Prostate for Patients With Lower Urinary Tract Symptoms and Localized Prostate Cancer. Clin Genitourin Cancer. 2013;11(3):251-5. PubMed PMID: 23375828.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer. AU - Liu,Ranlu, AU - Luo,Fei, AU - Zhang,Zhihong, AU - Xu,Yong, Y1 - 2013/01/29/ PY - 2012/10/11/received PY - 2012/12/19/revised PY - 2012/12/19/accepted PY - 2013/2/5/entrez PY - 2013/2/5/pubmed PY - 2014/4/1/medline KW - Brachytherapy KW - IPSS KW - Quality of life SP - 251 EP - 5 JF - Clinical genitourinary cancer JO - Clin Genitourin Cancer VL - 11 IS - 3 N2 - INTRODUCTION/BACKGROUND: Many localized PCa patients with preexisting LUTS are considered poor candidates for seed implants because of the greater risk of postoperative urinary morbidity. We report our department's experience with performing deferred LTURP 6 months after iodine-125 seed implantation to treat localized PCa patients with LUTS. PATIENTS AND METHODS: Of 225 men undergoing prostate brachytherapy at our institution between 2005 and 2011, 38 patients were treated with deferred LTURP 6 months after (125)I seed implantation. LTURP was considered after brachytherapy for patients whose International Prostate Symptom Score (IPSS) was greater than 12, or who still need a catheter for an elevated postvoid residual (PVR) (>100 mL) after α-blocker therapy for LUTS for 6 months. IPSS, quality of life (QOL) score, peak flow rate (PFR), and PVR were evaluated before and after LTURP. RESULTS: All 38 patients in our series underwent LTURP 6 months after prostate brachytherapy for low- or intermediate-risk PCa. Mean IPSS, QOL score, PFR, and PVR were significantly improved after LTURP, and improvement persisted at the latest follow-up. After a mean of 32 months of follow-up, no patient developed retention, urethral necrosis, or urinary incontinence after brachytherapy and LTURP. CONCLUSION: Iodine-125 seed implantation and deferred LTURP 6 months after brachytherapy is a safe and effective treatment strategy for patients with both LUTS and localized prostate cancer. SN - 1938-0682 UR - https://www.unboundmedicine.com/medline/citation/23375828/Iodine_125_seed_implantation_and_deferred_transurethral_resection_of_the_prostate_for_patients_with_lower_urinary_tract_symptoms_and_localized_prostate_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1558-7673(12)00249-2 DB - PRIME DP - Unbound Medicine ER -